ZIOPHARM Oncology awarded a $5,000 grant in support of the Sarcoma Alliance's Assistance Fund program. The grant will help support program costs and the development of a brochure describing the program. Ziopharm is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. The Company is currently focused on several clinical programs. One program for sarcoma is currently in a Phase III trial.
Palifosfamide (Zymafos(tm) or ZIO-201) is a novel DNA cross-linker in class with bendamustine, ifosfamide, and cyclophosphamide. ZIOPHARM is currently enrolling patients in a randomized, double-blinded, placebo-controlled Phase III trial with palifosfamide administered intravenously for the treatment of metastatic soft tissue sarcoma in the front-line setting. The company is also currently conducting a Phase I intravenous study of palifosfamide in combination with standard of care addressing small cell lung cancer and an oral form of the drug for treatment of solid tumors is currently in the advanced preclinical stage of development.
ZIOPHARM's operations are located in Boston, MA and Germantown, MD with an executive office in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.
On behalf of everyone we serve, a big thank you to Ziopharm.
8 months ago
1 comment:
Great people involved here. These guys will change oncology within the next few years.
Post a Comment